Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients

Drugs and Aging

Volumn 29, Issue 7, 2012, Pages 523-531

  Arnstein, Paul M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adverse drug reactions; Elderly; Guideline utilisation; Nonsteroidal anti inflammatories; Osteoarthritis; Prescribing; Topical

Indexed keywords

ACETYLSALICYLIC ACID; ACRIL; ACTRON; ADCO INDOMETHACIN GEL; ALGOGEL; ANALGESIC AGENT; APRENIN; ATROSILENE GEL; ATROXICAM; BENZYDAMINE; BREXIVEL; BRUXICAM; BUFEN; BUFEXAMAC; CAPSAICIN; CLEVIAN GEL; CORTICOSTEROID; CROXARYL; CYCLOOXYGENASE 2 INHIBITOR; DEALGIC; DICLOFENAC; DICLOFENAC DIETHYLAMINE; DICLOFENAC EPOLAMINE; DICLOFENAC GNR GEL; DICLOREUM TISSUGEL; DOLINAC GEL; DOLOFAST; ETOFEN GEL; ETOFENAMATE; EUROXI; FELBINAC; FELDENE LIPO; FELDENE TOPICO GEL; FLECTOR EP GEL; FLECTOR EP TISSUGEL; FLODOL; FLOGOPROFEN; FLURBIPROFEN; GLYCOSAMINOGLYCAN; IBULEVE; IBUPROFEN; IBUPROFEN LYSINE; IBUPROXAM; INDOMETACIN; IPROGEL; KETARTRIUM; KETOPROFEN; KETOPROFENE GNR; KETOPROFENE LBI; KLS GEL SPRAY; LAMOPOFLEX; METHADONE; MOBILAT GEL; NAPREBEN; NAPROSSENE; NAPROSYN GEL; NAPROXEN; NEOEBLIMON; NIFLUGEL R; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NUMIDAN GEL; OKI; OPIATE; OPTIFEN GEL; OPTIFEN GEL FORTE; ORPHENADRINE CITRATE; OXICAM DERIVATIVE; OXYPHENBUTAZONE; PARACETAMOL; PARFENAC FETTSALBE; PIROXICAM; PIROXICAM GNR; REUCAM; REUDENE; REUMAGIL; RIACIN; ROXEDIN; ROXENE; ROXENIL; SALICYLIC ACID METHYL ESTER; SALIENT; SOLARASE; SULPROTIN; SUPROFEN; THERMALGEN; TICOFLEX GEL; TOLECTIN GEL; TOLMETIN; TRAMADOL; TRANSACT LAT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGING; ARTHRALGIA; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFUSION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ELDERLY CARE; GASTROINTESTINAL TOXICITY; HAND OSTEOARTHRITIS; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; KNEE OSTEOARTHRITIS; LETHARGY; LIVER FUNCTION TEST; MEDICAL DECISION MAKING; MYALGIA; NEPHROTOXICITY; NOTE; OSTEOARTHRITIS; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SKIN IRRITATION; TACHYPNEA; TINNITUS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IRRITANTS; OSTEOARTHRITIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84862904480     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11631550-000000000-00000     Document Type: Note

References (70)

1. Lawrence RC, Felson DT, Helmick CG, et al., on behalf of the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008 Jan; 58 (1): 26-35
2. Sadosky AB, Bushmakin AG, Cappelleri JC, et al. Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity. Arthritis Res Ther 2010; 12 (4): R162. doi: 10.1186/ar3121
3. Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs 2011; 71 (10): 1259-79
4. Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2010 Oct 8; 59 (39): 1261-5
5. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998 Aug; 41 (8): 1343-55 (Pubitemid 28373113)
6. Rossignol M, Leclerc A, Allaert FA, et al. Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure. Occup Environ Med 2005 Nov; 62 (11): 772-7 (Pubitemid 41565012)
7. Grotle M, Hagen KB, Natvig B, et al. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008 Apr; 35 (4): 677-84 (Pubitemid 351500066)
8. Salaffi F, Carotti M, Stancati A, et al. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005 Aug; 17 (4): 255-63 (Pubitemid 46190142)
9. Centers for Disease Control and Prevention (CDC). Osteoarthritis. Atlanta (GA): CDC, 2010 [online]. Available from URL: http://www.cdc.gov/arthritis/ basics/osteoarthritis.htm [Accessed 2011 Aug 8]
10. Hochberg MC, Altman RD, Toupin April K, et al. American College of Rheumatology 2012 recommendations for the use of non-pharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012 Apr; 64 (4): 465-74
11. Jordan KM, Arden NK, Doherty M, et al., on behalf of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). EULAR Recommendations 2003: an evidence based approach to themanagement of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145-55 (Pubitemid 37500619)
12. National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. London: National Institute for Health and Clinical Excellence, 2008 Feb. NICE clinical guideline 59
13. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008 Feb; 16 (2): 137-62 (Pubitemid 351222155)
14. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987 Dec; 147 (12): 2093-100 (Pubitemid 18008711)
15. Roth SH. Nonsteroidal antiinflammatory drug gastropathy: we started it, why don't we stop it? J Rheumatol 2005 Jul; 32 (7): 1189-91 (Pubitemid 40995368)
16. Bombardier C, Laine L, Reicin A, et al., on behalf of the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 2000 Nov 23; 343 (21): 1520-8
17. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl JMed 2005Mar 17; 352 (11): 1092-102 (Pubitemid 40365350)
18. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005 Apr 5; 142 (7): 481-9
19. Solomon SD, McMurray JJ, Pfeffer MA, et al., on behalf of the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005 Mar 17; 352 (11): 1071-80 (Pubitemid 40365348)
20. Becker MC, Wang TH, Wisniewski L, et al., on behalf of the PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of non-steroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009 Apr; 157 (4): 606-12
21. Turajane T, Wongbunnak R, Patcharatrakul T, et al. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai 2009 Dec; 92 Suppl. 6: S19-26
22. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006 Jan; 54 (1): 282-91 (Pubitemid 43122213)
23. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007 Jul; 61 (7): 1181-7 (Pubitemid 46934629)
24. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010 Jan; 112 (1): 226-38
25. Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol 2011 Jul; 165 (1): 5-17
26. Roy S, Wang J, Kelschenbach J, et al.Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 2006 Mar; 1 (1): 77-89 (Pubitemid 44257502)
27. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: emergency department visits involving adverse reactions to medications among older adults. Rockville (MD): US Department of Health and Human Services, 2011 Feb 24. SAMHSA Publication no. DAWN 013
28. Walker PC, Alrawi A, Mitchell JF, et al. Medication use as a risk factor for falls among hospitalized elderly patients. Am J Health Syst Pharm 2005 Dec 1; 62 (23): 2495-9 (Pubitemid 41720566)
29. Hausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch of Phys Med Rehabil 2001 Aug; 82 (8): 1050-6 (Pubitemid 32744331)
30. Alexander BH, Rivara FP, Wolf ME. The cost and frequency of hospitalization for fall-related injuries in older adults. Am J Public Health 1992 Jul; 82 (7): 1020-3
31. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010 Dec 13; 170 (22): 1979-86
32. Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998 Nov 1; 148 (9): 887-92 (Pubitemid 28484108)
33. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 40-50 (Pubitemid 29044265)
34. Miller M, Stürmer T, Azrael D, et al. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc 2011 Mar; 59 (3): 430-8
35. Von Korff M, Merrill JO, Rutter CM, et al. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain 2011 Jun; 152 (6): 1256-62
36. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331-46
37. Perucca E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol 2007; 81: 183-99
38. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18 (11): 837-51 (Pubitemid 34073129)
39. Wynne H. Drug metabolism and ageing. J Br Menopause Soc 2005 Jun; 11 (2): 51-6 (Pubitemid 40872876)
40. Arnstein P. Balancing analgesic efficacy with safety concerns in the older patient. Pain Manag Nurs 2010 Jun; 11 (2 Suppl.): S11-22
41. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000 Sep; 60 (3): 555-74
42. Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res 2010 Dec 20; 4: 11-24
43. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Jun; 143 (3): 238-45
44. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31 (10): 2002-12 (Pubitemid 39336727)
45. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010 Jun; 37 (6): 1236-43
46. Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res 2011; 4: 159-67
47. Lin J, Zhang W, Jones A, et al. Efficacy of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004 Aug; 329 (7461): 324. doi: 10.1136/bmj.38159.639028.7C
48. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52 (Pubitemid 37553153)
49. Jakobsson U, Hallberg IR. Quality of life among older adults with osteoarthritis: an explorative study. J Gerontol Nurs 2006 Aug; 32 (8): 51-60
50. Carr DB. When bad evidence happens to good treatments. Reg Anesth Pain Med 2008 May-Jun; 33 (3): 229-40 (Pubitemid 351545851)
51. American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): AAOS, 2008 [online]. Available from URL: http://www.aaos.org/research/guidelines/ OAKguideline.pdf [Accessed 2011 Aug 1]
52. Lim AY, Doherty M. What of guidelines for osteoarthritis? Int J Rheum Dis 2011 May; 14 (2): 136-44
53. Simon LS, Lipman AG, Jacox AK, et al. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. 2nd ed. Glenview (IL): American Pain Society, 2002. Clinical practice guidelines no. 2
54. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006 Jan 25; (1): CD004257
55. Trnavský K, Fischer M, Vögtle-Junkert U, et al. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis: results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004 Mar; 31 (3): 565-72 (Pubitemid 38337620)
56. Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005 Dec; 32 (12): 2384-92 (Pubitemid 41780652)
57. Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004 Apr 24; 328 (7446): 995. doi: 10.1136/bmj.38040.607141.EE
58. Voltaren® Gel (diclofenac sodium topical gel) 1% [US prescribing information]. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2009
59. PENNSAID® (diclofenac sodium topical solution) 1.5% w/w [US prescribing information]. Hazelwood (MO): Mallinckrodt Brand Pharmaceuticals, Inc., 2010
60. US Food and Drug Administration. FDA drug safety communication: Voltaren Gel (diclofenac sodium topical gel) 1%: hepatic effects labeling changes. 2009 Dec 4 [online]. Available from URL: http://www.fda.gov/safety/medwatch/ safetyinformation/safetyalertsforhumanmedicalproducts/ucm193047.htm [Accessed 2011 Aug 9]
61. Matthews P, Derry S, Moore RA, et al. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev 2009 Jul 8; (3): CD007403
62. O'Malley P. Sports cream and arthritic rubs: the hidden dangers of unrecognized salicylate toxicity. Clin Nurse Spec 2008 Jan-Feb; 22 (1): 6-8
63. Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45 (2): 95-131
64. Tiso RL, Tong-Ngork S, Fredlund KL. Oral versus topical ibuprofen for chronic knee pain: a prospective randomized pilot study. Pain Physician 2010 Sep-Oct; 13 (5): 457-67
65. Chan FK. Primer: managing NSAID-induced ulcer complications: balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006 Oct; 3 (10): 563-73 (Pubitemid 44489589)
66. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009 May; 103 (9): 1227-37
67. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009; 69 (1): 51-69
68. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 Oct 4; 296 (13): 1633-44 (Pubitemid 44511610)
69. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007 Aug 3; 8: 73. doi: 10.1186/1471-2474-8-73
70. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. JRheumatol 2002Apr; 29 (4): 804-12 (Pubitemid 34303877)